Our data indicated that miR-126-5p may negatively regulate ADAM9 to promote the sensitivity of clinical DDP treatment of NSCLC and be a potential therapeutic target for NSCLC treatment. The gene discussed is ADAM9; the disease is non-small cell lung carcinoma.